VeriSIM Life
Predicts clinical success of drug candidates using biosimulation and machine learning.
What they do
VeriSIM Life offers BIOUST, an artificial intelligence driven biosimulation platform. Pharmaceutical and biotech researchers use the platform to predict how drug candidates will perform in animals and humans, reducing reliance on physical testing and preventing clinical trial failures.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Translational prediction
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2017
- Total funding
- $25M raised
Notable investors: Morpheus Ventures, RRE Ventures, Intel Capital, Siri Ventures.